261.07USD+3.99%Mkt Cap: 461.26B $P/E: 127.984d ago
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimm…
Industry Peers
Drug Manufacturers - Generalvs Drug Manufacturers - General
P/E
Pricier
Div Yield
Avg
1M Perf
Lower
$1.07TUSDP/E 42.6
$624.26BUSDP/E 30.0
$307.10BUSDP/E 21.1
$313.12BUSDP/E 35.7
$278.99BUSDP/E 22.3
$287.55BUSDP/E 28.7
$272.43BUSDP/E 22.1
$268.95BUSDP/E 28.0
$206.99BUSDP/E 11.7
$197.77BUSDP/E 25.5
$160.92BUSDP/E 17.6
$135.19BUSDP/E 18.1
$115.79BUSDP/E 15.9
$96.93BUSDP/E 18.8
$86.34BUSDP/E 14.0
$54.65BUSD
$30.78BUSDP/E 22.4
MRV
Marvell Technology, Inc.$25.88BUSDP/E 9.8
$11.38BUSDP/E 22.9
$10.80BUSDP/E 18.8
$10.72BUSDP/E 18.6
$6.71BUSDP/E 14.9
$3.56BUSDP/E 14.6
$2.96BUSDP/E 18.1
$56.76MUSD
$40.13MUSD
ELXR
Elixxer Ltd.$9.51MUSD
FLXN
Horizon Flexible Income ETF—P/E 27.3
ROSE
DocMorris AG—
CELG-RI
Bristol-Myers Squibb Company Ce—
Indicators:|
Key Statistics
Company
Market Cap461.26B $
Enterprise Value508.16B $
Revenue (TTM)62.82B $
Gross Profit42.96B $
Net Income (TTM)4.23B $
Revenue/Share35.50 USD
Last Price261.07 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees57.0K
CountryUS
SectorHealthcare
IndustryDrug Manufacturers - General
ISINUS00287Y1091
Valuation
P/E (Trailing)127.98
P/E (Forward)15.47
PEG0.41
EV/EBITDA16.99
EV/Revenue8.09
P/S7.08
P/B-66.80
EPS (TTM)2.03
EPS (Forward)16.26
52W Range
184.3999% of range261.64
52W High261.64 USD
52W Low184.39 USD
Profitability
Gross Margin70.24%
Oper. Margin32.16%
EBITDA Margin47.62%
Profit Margin6.91%
ROE-129.24%
ROA3.15%
Growth
Revenue Growth12.40%
Earnings Growth-46.20%
Cash Flow & Leverage
Operating CF19.03B $
CapEx (TTM)1.21B $
FCF Margin33.13%
FCF Yield4.51%
Net Debt63.52B $
Net Debt/EBITDA2.12
Balance Sheet
Debt/Equity-20.64
Current Ratio0.80
Quick Ratio0.52
Book Value/Sh-3.7670 USD
Cash/Share5.315 USD
Dividends
Fwd Div Rate6.920 USD
Trail. Div Rate6.740 USD
Div. Yield2.75%
5Y Avg Yield3.60%
Payout Ratio325.98%
Ex-Div DateJul 15, 2026
Pay DateAug 14, 2026
Analyst Consensus
Rating1.8 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)254.38 USD
Upside (mean)-2.6%
Target Range200.00 USD – 328.00 USD
$200.00-2.6% to mean$328.00
# Analysts29
Ownership
Shares Out.1.77B
Float1.76B
Insiders0.11%
Institutions76.87%
Short Interest
Short Ratio4.5d
Short % Float1.48%
Short % Out.1.33%
Shares Short23.45M
Short (prev mo.)22.59M
Technical
SMA 50215.69 (+21.0%)
SMA 200221.47 (+17.9%)
Beta0.31
S&P 52W Chg20.05%
Avg Vol (30d)4.50M
Avg Vol (10d)12.37M
Technical Indicators
RSI (14)77.9
MACD10.0703
MACD Signal6.9533
MACD Hist.+3.1169
BB Upper258.15 USD
BB Middle231.85 USD
BB Lower205.55 USD
BB Width22.69%
ATR (14)6.644 USD
Vol Ratio (20d)0.99x